Ultragenyx’ Mepsevii has been cleared for use in Europe to treat the ultra rare disease mucopolysaccharidosis type VII (MPS VII), offering patients an approved treatment for the very first time.
Read More
US regulators have approved the first drug to treat adults and children with x-linked hypophosphatemia (XLH), a rare, inherited form of rickets.
Read More
Doctors can now treat children living in the EU with the rare, chronic progressive musculoskeletal disorder X–Linked Hypophosphataemia with Kyowa Kirin/Ultragenyx’ Crysvita following its conditional approval in the region.
Read More
